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UV–visible and dichroic spectrum analysis and electron microscopy have been used to characterize a new amphotericin B (AmB) lipid
formulation prepared by a solvent displacement process. The composition was dimyristoylphosphatidylcholine (DMPC) and
dimyristoylphosphatidylglycerol (DMPG) in molar ratio DMPC/DMPG/AmB 7:3:5, a similar composition to that of AbelcetR. Although
the latter has a ‘‘ribbon-like’’ structure, our process gave a thin disc-like structure. Analysis of circular dichroism (CD) and UV–visible
spectra of formulations containing different percentages of AmB revealed that a minimum of AmB self-association was observed with 7:3:5
molar ratio. Varying the lipid ratio (DMPC/DMPG) while maintaining the fixed ratio of AmB yielded similar results when DMPC was in
excess (DMPC/DMPG from 10:0 to 6:4). However, when the ratio was between 5:5 to 3:7, AmB self-aggregation increased. For
compositions rich in DMPG (2:8 and 0:10), inversion of the CD spectrum was observed. The influence of the lipid composition on the
morphology of the complex was also evident in electron microscopy. DMPC/DMPG/AmB (10:0:5) gave large unfracturable lamellae. The
presence of DMPG shortened the lamellae, which often appeared as disc-like structures. AmB content, the presence of DMPG and the
preparation process all contribute to generating these original structures with particular CD spectra.
D 2004 Elsevier B.V. All rights reserved.Keywords: Amphotericin B; Circular dichroism spectrum; UV–visible spectrum; Electron microscopy; Interdigitated structure; DMPC; DMPG
1. Introduction region. The head of the molecule consists of a carboxylAmphotericin B (AmB) is considered to be the antifungal
agent of choice for the treatment of disseminated infections
in immunocompromised patients (cancer, transplants or
AIDS), despite its toxicity.
In fact, both the activity and the toxicity of AmB are
related to its structure (Fig. 1) and its tendency to associate
with itself and with lipids. Structurally, this antibiotic
possesses a macrolide ring, containing an internal ester or
lactone, a heptane chromophore, and a hydroxyl hydrophilic0005-2736/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2004.05.003
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E-mail address: Gillian.Barratt@cep.u-psud.fr (G. Barratt).group and an amino sugar, the latter being attached to the
macrolide ring through a glycosidic linkage.
The therapeutic potential of AmB and other polyene
antibiotics is determined by their affinity for cholesterol
and ergosterol, the principal sterols in eucaryote cell mem-
branes. The selectivity for these sterols depends on the
aggregation state of AmB [1]. Monomeric AmB associates
with the sterols in fungal cell membranes, whereas self-
associated AmB can also form pores in cholesterol-contain-
ing membranes, leading to toxicity towards host cells.
Strategies aimed at improving the therapeutic index of
AmB have attempted to minimise the amount of self-
associated AmB by complexing the antibiotic within
lipid-based formulations (liposomes, complexes, emul-
sions) from which it is released progressively in the
Fig. 1. Structure of AmB.
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reduction of AmB toxicity with this type of formulation,
and three of them are now available commercially. In the
last decades, many studies have addressed the interactions
between AmB and lipids, especially those involved in the
toxicity of AmB and in pore formation (sterols). Different
techniques have been employed, the most frequently used
being UV–visible absorbance, circular dichroism (CD),
electron microscopy, NMR, X-ray diffraction and differen-
tial scanning calorimetry (DSC). These studies of the
interactions between AmB and lipids were particularly
useful during the development of the commercial formu-
lations of AmB: AmBisomeR [2], AbelcetR [3] and
AmphotecR [4]. One of these formulations, AbelcetR,
consists of AmB associated with two phospholipids:
dimyristoylphosphatidylcholine (DMPC) and dimyristoyl-
phosphatidylglycerol (DMPG), in a ratio of 7:3, organized
in a ‘‘ribbon-like’’ structure [3,5]. However, the large size
of this lipid assembly, about 3 Am, favours its rapid
clearance from blood and accumulation in organs rich in
phagocytic cells, leading to a reduction in its antibiotic
activity [6,7].
In the present work, a solvent displacement process
had been used to prepare a colloidal dispersion of AmB
and phospholipids with the same composition as
AbelcetR, but with a smaller, controlled, particle size.
To characterize this formulation, among the techniques
mentioned above, we chose to use spectroscopic measure-
ments: electronic absorption and CD [8]. The particular
structure of AmB molecule means that such techniques
are especially appropriate to study its aggregation stateunder different conditions. Of the two, CD spectroscopy
is more suitable for detecting the aggregated form of AmB.
We have correlated the results of spectroscopic analysis
with zeta potential measurements and electron microscopy
in order to characterize this original formulation and to
explain its mechanism of formation.2. Materials and methods
2.1. Materials
Amphotericin B powder and FungizoneR were pur-
chased from Squibb (Neuilly, France). AbelcetR (3 Am
diameter), AmB lipid complex preparation based on
DMPC:DMPG (7:3, mol/mol) was provided by the Lipo-
some Company Ltd. (London, UK). Amphotec was
obtained from Liposome Technology Inc. (Menlo Park,
CA, USA). DMPC and DMPG were purchased from Avanti
Polar Lipids Inc. (Alabaster, Alabama, USA). Solvents and
other reagents were obtained from Carlo Erba reagenti (Val
de Reuil, France).
2.2. Preparation of lipid complex of AmB (LC-AmB)
A colloidal dispersion was prepared using the solvent
displacement process described by Stainmesse et al. [9].
AmB (3.5 mg in 10 ml of methanol, 0.35 mg/ml) was added
to organic solvent containing different ratios of DMPC/
DMPG (5 ml of methanol) at 40 jC. This organic phase (15
ml) was then added to a water phase (MilliQR water, 15 ml,
Waters Millipore, France) under magnetic stirring at room
temperature (around 20 jC). The volume was reduced by
low pressure solvent evaporation until a volume of 5 ml.
The AmB/phospholipids ratios varied between 5% and 50%
(w/w; at ratios higher than 50% the formulation precipitat-
ed) and DMPC/DMPG ratios between 10:0 and 0:10, mol/
mol. As a control, AmB was also precipitated alone, without
lipid, by the same process.
2.3. Size measurement
The mean particle diameter was measured by photon
correlation spectroscopy (PCS) with a Nanosizer N4 (Coul-
tronics, Margency, France).
2.4. Zeta potential
The zeta potential of the formulations was determined by
Doppler velocimetry and PCS on a Zetasizer 4 (Malvern
Instruments, UK). The different formulations were analysed
without further dilution. AmB precipitated alone at a final
concentration of 5 10 4 M or less did not yield sufficient
light-scattering properties to make a valid measurement. The
pH of all formulations was similar to the pH of MilliQR
water, pH = 6.25, at room temperature.
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Absorbance measurements were made by using a Cary
1E UV–visible spectrometer (Varian, France). The drug
concentrations in dispersions were calculated from absor-
bance at 405 nm after appropriate dilution in methanol
(emethanol 150000 M
 1 cm 1). The CD spectra were
recorded with a Jobin–Yvon Mark V dichrograph, and
expressed as De (M 1 cm 1), is the differential molar
absorption dichroic coefficient.
These spectroscopic measurements were made at room
temperature (around 20 jC) after dilution in water to final
AmB concentrations of 50, 10, 5 and 110 6 M (path-
lengths of quartz cuvettes: 0.2, 1, 2, 5 and 10 cm) to
evaluate the aggregation state of AmB in the different
formulations.
2.6. Electron microscopy
Freeze Fracture: a drop of the suspension containing 30%
glycerol as a cryoprotectant was deposited on a thin copper
planchett and rapidly frozen in liquid propane. Fracturing
and shadowing using Pt-C were performed in a Balzers BAF
310 freeze-etch unit. The replicas were examined with a
Philips 410 electron microscope.
Air Drying: the sample was deposited on a fresh
cleaved mica plate, dried at room temperature and shad-
owed in the Balzers Units. The shadowing using Pt-C
was performed in a Balzers BAF 310 freeze-etch unit.
The replicas were examined with a Philips 410 electron
microscope.
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3.1. Size and polydispersity
The size and polydispersity of AmB lipid preparations
depended on the AmB/phospholipids ratio when the
phospholipid composition was DMPC/DMPG 7:3 (molar
ratio). Optimal size and minimal polydispersity were
obtained with AmB at 35% of total weight of phospho-
lipids (Table 1A).
Modification of the proportions of the two phospholipids
(DMPC/DMPG) modified the size and the polydispersity,Table 1A
Evolution of size, polydispersity and zeta potential with the ratio of AmB (w/w)
methods
AnmB/Lipid ratio
(w/w)
0% 2.5% 5% 10% 20% 30%
Size (nm) 690F 129: 79% 559
>1000 >1000 >1000 >1000 184F 57: 21% 157
Polydispersity 0.68 0.512 0.45 1.2 0.512 0.56
Zeta potential
(mV)
 55.1  67.1  60.8  55.0  46.3  4the optimal ratio giving small size and polydispersity being
the ratio 7:3. This optimal ratio is the same as that in
AbelcetR (Table 1B).
The optimal formulation (DMPC/DMPG/AmB 7:3:5
referred to as LC-AmB) was stable for 6 months after
preparation when stored at + 4 jC, with no change in size.
Other formulations increased in size a few days after the
preparation with or without precipitation.
3.2. Zeta potential
The zeta potential of AmB of LC-AmB:  43.8 mV,
Table 1A, was intermediate between that of AmB precipi-
tated alone (around  27 mV, Table 1C) and the lipids alone
( 55 mV, Table 1A). Increasing the proportion of AmB up
to 30% (w/w) reduced the absolute value of the zeta
potential (Table 1A).
3.3. Spectroscopic analysis of AmB alone
3.3.1. UV–visible absorbance of AmB alone
When AmB from a stock solution in DMSO was diluted
in water at a sub-micellar concentration ( < 10 7 Ag/ml,
10 7 M) the absorbance spectrum showed three bands at
410, 385, 365 nm and a smaller band at 344 nm charac-
teristic of the monomeric form [8]. As the AmB concen-
tration was increased up to 10 5 M, the small band at 344
nm increased in intensity and the other three bands
underwent red shifts from 410 to 420 nm, from 385 to
390 nm and from 365 to 368 nm, together with a reduction
in intensity, indicating the appearance of the self-associated
form [8].
AmB was also prepared by the solvent displacement
process at concentrations corresponding to 10%, 35% and
50% (w/w) in the complex but without phospholipids. The
spectra of these preparations, recorded at a final concen-
tration of 5 10 5 M in water, were different from those
of AmB solubilized in methanol at a final concentration of
5 10 5 M in water. For the preparations corresponding
to the two highest ratios, four absorption bands were seen,
the main one at 344 nm and three others at 365, 385 and
420 nm in decreasing order of intensity (Fig. 2A). A
similar spectrum was seen for AmB prepared at the lowest
concentration, but with a blue shift of the principal band to
326 nm.of LC-AmB with ratio DMPC/DMPG 7:3, as described in Materials and
35% 40% 45% 50%
F 161: 66% 248F 158: 87% 275F 78: 93%
F 46: 34% 303F 53 368F 115 >1000: 13% >1000: 7%
0.16 0.278 0.35 0.45
6.3  43.8  42.8  43.2  45.9
Table 1B
Evolution of size and polydispersity as a function of the molar ratio of lipids (DMPC/DMPG) of LC-AmB as described in Materials and methods with the total
lipids/AmB molar ratio fixed to 10:5
DMPC/DMPG 10:0 9:1 8:2 7:3 6:4 5:5 4:6 3:7 2:8 1:9 0:10
Size (nm) >1000: 87% 311F128: 91% 284F 75: 79%
>1000 209F 42: 13% >3000 303F 53 >1000: 9% 381F 207 436F 273 339F 131 418F 131 93F 21: 21% 396F 101
Polydispersity 1.5 0.51 2.1 0.16 0.35 0.49 0.58 0.27 0.35 0.48 0.56
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The monomeric form of AmB yielded a CD spectrum
with three weak positive bands at 410, 385 and 365 nm.
On the other hand, the CD spectrum of the aggregated
form of AmB displayed a very intense dichroic doublet
centered at 344 nm as well as negative bands at 420, 390
and 368 nm [8].
The CD spectrum of AmB prepared according to the
solvent displacement process starting with various quantities
of AmB (10, 35, and 50%) showed a modification of the
center of the dichroic doublet (327, 335, 337, respectively)
and of its intensity (De (M 1 cm 1): 4500, 2500, 2800,
respectively) for a diluted to give a final AmB concentration
of 5 10 5 M. The negative minimum of the CD doublet
band was at 350 nm for 35%, and 50% but was at 336 nm
for 10% w/w (Fig. 2B).
3.4. Effect of varying AmB–lipid ratio
3.4.1. UV–visible absorbance
Spectra were recorded for the LC-AmB formulations
prepared at a constant lipid concentration (ratio: DMPC/
DMPG 7:3) with different percentages of AmB, diluted to
give an final AmB concentration of 5 10 5 M. For the
ratio 10%, the bands at 333 and 344 nm had similar
intensity and were more intense than the other bands (365,
385 and 415 nm; Fig. 3). However, for AmB ratios between
20% and 50% (w/w), the intensity of the whole spectrum
decreased with increasing proportions of AmB, and a
minimum intensity was obtained with the 35% ratio, as
shown in Fig. 3.
3.4.2. CD
When the AmB–lipid complexes (LC-AmB) were ex-
amined by CD (10% to 50% AmB, Fig. 4), the dichroic
doublet characterising the aggregation state of AmB wasTable 1C
Evolution of size, polydispersity and zeta potential with the ratio of AmB
without lipids prepared by the process like LC-AmB as described in
Materials and methods
AmB (w/w) without lipids 10% 35% 50%
Size (nm) 1900F 355: 60% 2750F 250: 65%
>1000 275F 40: 40% 350F 100: 35%
Polydispersity 0.35 0.62 1.2
Zeta potential (mV)  29.6  28.7  24.3still observed, but the intensity and the center of the dichroic
band varied according to the percentage of AmB. The
dichroism spectra of the complexes with AmB ratios up to
and including 20% were similar to the spectrum of AmB
alone (Fig. 4): a doublet centered on 340 nm and negative
bands at 368, 389 and 419 nm. For ratios above 20%, the
intensity was lower and the negative bands were progres-
sively replaced by three positive bands (420, 392, 375 nm)
which had a similar intensity whatever the ratio. TheFig. 2. (A) Evolution of electronic absorbance spectra of AmB obtained by
displacement solvent procedure (at different initial concentration: 1.0, 3.5
and 5.0 mg) as described in Materials and methods. (B) Evolution of CD
spectra (DeL–R 10 3 (M 1 cm 1)) of AmB obtained by displacement
solvent procedure at different initial concentration as described in Materials
and methods.
Fig. 3. Evolution of electronic absorbance spectra with different
percentages of AmB in AmB/lipid preparations (w/w) with a molar ratio
of DMPC/DMPG 7:3, obtained as described in Materials and methods.
(10%: ——; 20%: . . .. . .; 30%: – – – ; 35%: ; 40%: ;
50%: ).
M. Larabi et al. / Biochimica et Bioph176minimum doublet intensity was reached with the 35% ratio.
These positive bands are characteristic of interactions of
AmB with other molecules (in this case, lipids).
3.4.3. Influence of the dilution on CD and UV–visible
spectra
The LC-AmB 7:3:5 formulation was diluted 10 and 1000
times to give AmB concentrations of 5 10 6 and
5 10 8 M. There was no modification of the spectra,
indicating that AmB remained associated with the lipid.
Incubation for 1 h at 37 jC did not affect its spectrum (data
not shown).Fig. 4. Evolution of CD spectra (DeL–R 10 2 (M 1 cm 1)) with
different percentages (w/w) of AmB in AmB/lipid preparations with molar
ratios DMPC/DMPG 7:3, as described in Materials and methods. (20%:
; 30%: ; 35%: ; 40%:
; 50%: - - - -).3.5. Effect of DMPC/DMPG ratio with a fixed AmB ratio
(total lipids/AmB 10:5)
3.5.1. UV–visible absorbance
The UV–visible spectra observed for DMPC/DMPG
ratios between 10:0 and 6:4 were very similar to that
observed with the ratio 7:3:5 (Fig. 5). For the lipid ratios
between 5:5 and 0:10 (Fig. 5), the intensity of the band at
333 nm increased with increasing DMPG up to the ratio 2:8
(Fig. 5).
3.5.2. CD
Changing the proportions of the two phospholipids
(DMPC/DMPG) with the same ratio of AmB: 35% w/w or
5 molar ratio) between 10:0 and 6:4 yielded similar results
to the 7:3:5 formulation (Fig. 6A): the doublet was centered
around 335 nm with similar intensity, except for the 6:4:5
formulation in which it was slightly lower, and three similar
positive bands (420, 395, 376 nm). The ratios 5:5:5 and
4:6:5 showed spectra similar to that of AmB alone: the
dichroic doublet centered around 345 nm and three negative
bands at 368, 389, 419 nm (Fig. 6B). For the lipid ratios
3:7:5 to 0:10:5, the large positive band of the dichroic
doublet became negative and the positive bands (420, 389,
368, 352 nm) were very intense (50 times higher than the
ratio 7:3:5).
The DMPC/DMPG proportions were also varied for
other AmB ratios (10%, 40% and 50%), yielding similar
results to those for 35%.
3.6. Electron microscopy
AmB prepared by the solvent displacement method
without lipids appeared to be aggregated like a bunch of
grapes after air drying and shadowing (not shown). Freeze-
ysica Acta 1664 (2004) 172–181Fig. 5. Evolution of electronic absorbance spectra with different molar
ratios of DMPC/DMPG in the AmB/lipid preparations with 5 mol of AmB
for 10 mol lipid, obtained as described in Materials and methods. (10:0,
; 8:2, ; 7:3, ; 6:4, ; 5:5, ; 3:7,
– – – ; 2:8, ——; 0:10, ).
Fig. 6. (A) Evolution of CD (DeL–R 10 2 (M 1 cm 1)) spectra with
different molar ratios of DMPC/DMPG for 5 mol of AmB for 10 mol
lipid, obtained as described in Materials and methods. (B) Evolution of
CD (DeL–R 10 3 (M 1 cm 1)) spectra with different molar ratios of
DMPC/DMPG for 5 mol of AmB for 10 mol of lipids, as described in
Materials and methods.
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yielded a string-of-pearls structure of several microns (Fig.
7A). The addition of the lipid to the formulation in the ratio
7:3:5 resulted in non-fracturable disc structures as shown by
freeze-fracture (Fig. 7B) and shadowing after drying (Fig.
7C). The thickness of the disc was evaluated from the angle
of shadowing and the length of the shadow to be about
29 A˚.
Modification of the ratio of the two phospholipids
yielded different structures in freeze-fracture electron mi-
croscopy. Without DMPG (molar ratio DMPC/DMPG/AmB
10:0:5) large unfracturable lamellae were observed (Fig.
7D). The presence of DMPG favoured the formation ofshorter lamellar structures, both stacked and fused in
places (Fig. 7E) or a predominantly disc morphology
(Fig. 7B, C, F).4. Discussion
The amphotericin B molecule (Fig. 1) has a particular
cyclic structure with seven conjugated double bonds which
exhibit intense peaks of absorption between 250 and 450
nm. This means that electronic absorption and CD spectros-
copy are ideal tools to study the organisation of this
antibiotic. Such studies are useful both for attempting to
understand the interactions of AmB with fungal and mam-
malian cell membranes and, as in this study, for character-
ising lipid formulations of AmB designed to reduce its
toxicity. In consequence, the protocols used in the literature
are variable. Most studies have used low AmB/lipid ratios
( < 0.02), only those involving the commercial formulations
referred to above have used higher ratios similar to those in
this study. In some cases, such as the studies of Chen and
Bittman [10] and Jullien et al. [11], AmB was added to
preformed lipid membranes. However, in the case of phar-
maceutical formulations, the antibiotic is in contact with the
lipids and organic solvents during the preparation process.
The molecular state of AmB, and in particular its self-
aggregation in aqueous medium, depends on a number of
factors: its final concentration, pH, temperature and ionic
strength of the aqueous phase, the concentration and nature
of the original organic solution. Even in organic solvent
where AmB is in its monomeric form, the absorption and
CD spectra of AmB vary according to the medium, because
of influences on the k*pk transition. In our study, AmB
dissolved in a large volume of methanol either alone or with
lipids is added to an equal volume of water to form an
aqueous dispersion. This study shows a difference in the
aggregation state between AmB prepared by the solvent
displacement process and AmB dispersed in water from a
concentrated stock solution in methanol, with evidence of
AmB self-association (absorption band at 344 nm and a
dichroic doublet) after solvent displacement. Similar results
concerning the influence of the original solvent medium on
the state of AmB in aqueous dispersion were obtained by
Espuelas et al. [12]. The blue shift of the center dichroic
doublet from 337 to 327 nm can be interpreted as a super-
aggregated form of AmB, as observed by Gaboriau et al.
[13] for heat-treated AmB.
When AmB was formulated with lipids by the solvent
displacement process, the absorption and CD spectra indi-
cated an influence of the lipid on the aggregation state of the
AmB, which depended on the AmB/lipid ratio. Kawabata et
al. [14] observed that the amount of non-self-associated
AmB associated with lipids was inversely proportional to
the AmB/lipid ratio when the antibiotic was incorporated
into small unilamellar vesicles composed of DMPC/DMPG
in a 7:3 molar ratio. However, the maximum AmB/lipid
Fig. 7. Electron microscopy of AmB alone (A): prepared by solvent displacement evaporation, (freeze fracture, bar = 500 nm); AmB–lipid formulation with the
ratio DMPC/DMPG/AmB 7:3:5: (B) (freeze fracture, bar = 200 nm) and (C) (air drying and shadowing bar = 200 nm); 10:0:5: (D) (freeze fracture, bar = 500
nm); 5:5:5: (E) (freeze fracture, bar = 500 nm); 1:9:5: (F) (freeze fracture, bar = 500 nm). In some cases, for better visualisation, the samples were etched before
shadowing (D, E, F).
M. Larabi et al. / Biochimica et Biophysica Acta 1664 (2004) 172–181178ratio in this study was 0.1. In our study, AmB prepared with
lipids at 10% or less gave spectra similar to those of AmB
prepared alone and the band corresponding to monomeric
AmB associated with the lipids at 415 nm did not change,
suggesting a saturation of the interaction between the
monomer and lipids. This is correlated with the reduced
intensity of the dichroic doublet and the appearance of
positive bands in the higher range of the CD spectrum of
AmB at contents above 20% (Fig. 4).
The importance of the concentration of AmB for its
interaction with phospholipids had already been demon-
strated by Chen and Bittman [10] and Jullien et al. [11], but
for different lipid compositions and lower AmB/lipid ratios.
In our study, the ratios between 10% and 50% did not allow
all the AmB to be ‘‘dissolved’’ in the lipid in the monomeric
form. However, the interaction between the lipid and the
aggregated AmB was very stable since the absorption and
CD spectra of the preparation containing 35% AmB with
lipid were not affected by dilution down to 5 10 8 M
AmB. This proportion of AmB could be considered optimal
as a pharmaceutical formulation because it is generally
accepted that the origin of toxicity towards mammalian cell
membranes is free, self-associated AmB [1]. On the other
hand, the CD spectrum of AbelcetR was different from thatof our formulation, with a more intense dichroic doublet,
similar to that obtained with the composition 5:5:5 prepared
by the solvent displacement method. However, Perkins et al.
[15] have shown a reduction of the intensity of dichroic
doublet with the increase of AmB weight ratio with
ABLCk (AbelcetR, which was correlated with a reduction
of the AmB toxicity of this formulation [5].
In order to determine the role of the lipid composition in
the interactions with AmB, we varied the proportion of the
two phospholipids while keeping the total AmB/lipid ratio
at 35% AmB. Both spectral analysis and electron micros-
copy indicate that the type of objects obtained was strongly
influenced by the lipid composition. As far as the aggrega-
tion state of AmB is concerned, similar results were
obtained for the DMPC/DMPG ratios between 10:0 and
6:4. However, when the proportion of DMPG, a phospho-
lipid with a net negative charge on the polar head group at
physiological pH, was increased further, dramatic changes
were observed in the CD spectra. At ratios between 5:5 and
3:7, there was a red shift of the center of the positive part of
the dichroic doublet and a large increase in its intensity
(maximal at the ratio 4:6, peak height out of the scale),
while the negative part of the doublet resembled that
obtained with AmB alone. This could be interpreted as a
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to an absence of incorporation of the antibiotic molecule in
the complex. The instability and precipitation observed for
these preparations corroborate this hypothesis.
DMPG/DMPC ratios of 3:7 and 0:10 gave a completely
new CD spectrum which was inverted, with the negative
part at lower wavelengths and the positive part at higher
ones. An inverted spectrum for AmB was observed by
Milhaud and Michels [16], but under very different con-
ditions: AmB was associated with multilamellar vesicles of
dilauroylphosphatidylcholine at a very low AmB/lipid ratio
of 0.005. The spectrum obtained was very different from the
one presented here. Another study by the same group
concerning the interaction of the polyene antibiotic filipin
III with multilamellar vesicles of DMPC at an antibiotic/
lipid ratio of 0.25 may be more relevant [17]. Filipin differs
from AmB in that it is a smaller molecule, with five rather
than seven conjugated double bonds and in that it is
uncharged, lacking the amino sugar and the carboxyl group.
The spectrum obtained for filipin/DMPC had a negative
band at 308 nm and three positive bands at 324, 340 and
362 nm.
The strong association of filipin with DMPC was con-
firmed by DSC measurement of the phospholipid phase
transition, the enthalpy of which was reduced in parallel
with increasing antibiotic content [17]. We have observed
(unpublished results) similar decreases induced by AmB in
DMPC/DMPG mixtures at all lipid ratios, as did Janoff et al.
[3]. However, CD spectrum inversion only occurred with
high proportions of DMPG. This could indicate an electro-
static interaction between the negatively charged phospho-
lipid and the amino group of AmB. However, spectrum
inversion was not dependent on the AmB/lipid ratio: similar
results were observed with AmB contents of 10%, 40% and
50% (results not shown). Another explanation could be that
DMPG is in the gel state in water under the temperature and
pH conditions of this study. This could reduce the mobility
of AmB within the formulation and block it in a particular
configuration.
Electron microscopy also demonstrated the critical role
of the lipid composition. Although the spectra were not
influenced by the proportion of DMPG up to 40% of total
lipid, the morphology of complexes formed from AmB and
DMPC alone was completely different from that of ternary
AmB/DMPC/DMPG complexes. Molecular modelling
studies show that AmB can form stable aggregates with
DMPC by electrostatic interactions between the amino
group and the phosphate of the lipid head-group and that
this could contribute to pore formation in cholesterol-
containing membranes [18]. Similar structures have already
been seen by electron microscopy with this composition
[3,19]. The addition of DMPG to the system allows a disc-
like structure to be formed when DMPC remains in excess.
Amphotericin B is essential for this structure, which is not
seen with the lipids alone (results not shown). In particular,
the ‘‘optimal’’ formulation (7:3:5) yields a disc structure.An interdigitated structure was observed by Perkins et al.
[15] for the same composition, but in the form of ‘‘rib-
bons’’. These authors only observed this structure for the
7:3 ratio, but we cannot exclude the possibility that it could
also be formed for ratios 9:1, 8:2 and 6:4 in our study
because these compositions were not examined by electron
microscopy. The gel state of DMPG might induce the disc
structure; however, at equimolar proportions of DMPC and
DMPG, a very particular structure with discs fused at their
extremities was observed, while the 1:9 ratio again showed
individual discs.
Another AmB formulation which has a small disc-like
structure is AmphotecR, AmB and cholesteryl sulfate in a
1:1 molar ratio [20]. However, this shows a bilayer disc by
freeze fracture electron microscopy and not an interdigitated
structure. The CD and UV–visible spectra for AmphotecR
were similar to that of AmB–cholesterol described in the
literature (UV–visible spectrum, Fig. 8A: one large band at
332 and three smaller at 365, 386 and 406; CD spectra, Fig.
8B: 100 times less intense than that of LC-AmB, a dichroic
doublet center at 342 and three bands at 381, 400 and 426).
These differences indicate that the interactions between
AmB and the lipids were very different. In spite of the
difference in structure between AbelcetR [15] and LC-
AmB, spectrum analysis of the bands shows a similar
interaction (interdigitated) and organisation. However, the
different intensity of the bands reflects the different process
of preparation.
The spectra obtained with AmB alone prepared by the
process of nanoprecipitation were characterised by the
formation of a super-aggregate form in the formulation
equivalent to 10% of AmB (1 mg) [13] while the AmB
aggregation state with the concentration corresponding to
35% and 50% was similar to AmB in methanol diluted in
water. The dried and shadowed electron microscopy of
AmB alone prepared by the solvent displacement process
shows structures resembling a bunch of grapes while freeze-
fracture electron microscopy of the same preparation
yielded a string-of-pearls structure of several microns (Fig.
7A). This is different from the structure observed for
crystallised AmB, which is in the form of a bundle of
needles [21]. Grant et al. [19] also observed a different the
structure for AmB prepared like AbelcetR without lipids
(film dried down, hydrated with warming and dialysed
where appropriate: a suspension of amorphous material with
no similarity to lipid bilayers). The cut surfaces of the
resulting amorphous masses (fracture faces) were generally
smooth and featureless, etching to expose their outer surfa-
ces revealed the microspherular appearance, with grains
6.25–25 nm in size. This is probably the result of the
preparation process which allows AmB to assume a double
helical structure in aqueous dispersion as described by
Millie´ et al. [22], in which the hydrophobic parts are hidden
and the polar head groups are hydrated. This result could
show the importance of hydrophobic interactions in the
formation of AmB aggregates [23].
Fig. 8. (A) Electronic absorbance spectra of Amphotec diluted in water to give a final AmB concentration of 5 10 5 M obtained as described in Materials and
methods. (B) CD (DeL–R (M
 1 cm 1)) spectra of Amphotec diluted in water to give a final AmB concentration of 5 10 5 M obtained as described in
Materials and methods.
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potential ( 27 mV) at pH 6.25. Since the pKa values of
the amino group and the carboxyl group are 10 and 5.7,
respectively [24,25], a net positive charge would be
expected at this pH. However, a negative zeta potential
for AmB aggregates has already been noted by Witzke and
Bittman [26]. The explanation is that between pH 4 and 9
intermolecular electrostatic interactions within the aggre-
gates mask some positive charge, leaving the surface of
the aggregate negative [27,28]. Espuelas et al. [12] ob-
served a negative zeta potential for AmB aggregates
prepared by a process similar to that used in this study
for external pH values of 5–10. Below pH 4, intermolec-
ular interactions decrease and positively charged species
can be detected.
As expected, the objects formed from DMPC and DMPG
in the 7:3 molar ratio had a negative zeta potential ( 55 mV)
because of the net negative charge on the DMPG head group.
The interactions between the lipids would be essentially
hydrophobic and van der Waals forces, rather than electro-static interactions. Addition of AmB showed an increase in
the absolute value of the zeta potential with increasing AmB
ratio up to 35%AmB. Thereafter, the zeta potential value was
stable, up to 50% AmB. However, it is difficult to conclude
about the nature of the interaction between AmB and lipids
using only zeta potential data, because the values could be an
average of several different species.
These results clearly show that our solvent displacement
process leads to the formation of AmB–lipid structures
which are different are from the ‘‘ribbon-like’’ ones de-
scribed by Janoff et al. [3,5] for the same composition. Our
observations are consistent with a model of the antibiotic
intercalated between the phospholipids in an interdigitated
structure for the molar ratio DMPC/DMPG/AmB 7:3:5.
There was a strong interaction between AmB and lipids
(same analysis spectra after dilution suggest no dissocia-
tion). The reduction of free self-associated AmB and the
small size of the complexes could explain why this new
formulation has been found to be less toxic than AbelcetR
and to have a different biological activity [29,30].
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